DelveInsight’s “End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the End-Stage Renal Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The End-Stage Renal Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
End-Stage Renal Disease (ESRD): An Overview
End-Stage Renal Disease (ESRD) is a medical condition in which a person’s kidneys cease functioning on a permanent basis leading to the need for a regular course of long-term dialysis or a kidney transplant to maintain life. Patients may experience a wide variety of symptoms as kidney failure progresses. These include fatigue, drowsiness, decrease in urination or inability to urinate, dry skin, itchy skin, headache, weight loss, nausea, bone pain, skin and nail changes, and easy bruising.
Some of the risk factors for developing chronic kidney disease—that could ultimately lead to end-stage renal failure—include diabetes, high blood pressure, heart disease, drug abuse, blockages in the urinary tract, family history, inflammation, and some genetic disorders. Diabetic nephropathy (DN) is one of the most common complications of diabetes and the leading cause of the end-stage renal disease (ESRD). Approximately 30–40% of diabetes mellitus patients in the world progress to ESRD, which emphasizes the effect of genetic factors on DN.
End-Stage Renal Disease (ESRD) Market Key Facts
According to the United States Renal Data System, in 2015, there were 124,411 new ESRD diagnoses, reflecting an increasing burden of kidney failure. The prevalence of the disease has been rising at a stable number of about 20,000 cases per year. Kidney disease is the ninth leading cause of death in the United States. The cumulative incidence of end-stage renal disease is higher in males than females.
As per the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry, in 2019, 89,579 patients started renal replacement therapy (RRT) for ESRD within the countries and regions reporting to the ERA-EDTA Registry, resulting in an overall incidence of 132 per million population of all ages (pmp).
ESRD is more common in men than women; however, statistics vary little across different regions. Based on the US Renal Data System (USRDS) annual data report, the prevalence of chronic renal failure between the years 2007 and 2011 was higher in women (15.1%) than in men (12.1%). However, in the most recent US Renal Data System, 57.8% of the patients with a new onset ESRD were men.
End-Stage Renal Disease (ESRD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted End-Stage Renal Disease market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the End-Stage Renal Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
End-Stage Renal Disease (ESRD) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the End-Stage Renal Disease Epidemiology, Segmented as –
Total Prevalent Cases of End Stage Renal Disease (ESRD) in the 7M [2019–2032]
Gender-specific cases of ESRD in the 7MM [2019–2032]
Cause-specific cases of ESRD in the 7MM [2019–2032]
Diagnosed and Treatable cases of ESRD in the 7MM [2019–2032]
End-Stage Renal Disease (ESRD) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the End-Stage Renal Disease market or expected to be launched during the study period. The analysis covers the End-Stage Renal Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the End-Stage Renal Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the End-Stage Renal Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market
End-Stage Renal Disease (ESRD) Therapeutics Analysis
Treatment of end-stage renal disease involves correcting parameters at the level of the patient’s presentation. Interventions aimed at slowing the rate of kidney disease should be initiated and can include treating the underlying cause and managing blood pressure and proteinuria. Other targets in preventive care and monitoring should include tight glycemic control, cardiovascular risk reduction, and general lifestyle recommendations such as smoking cessation and dietary restriction.
Several major pharma and biotech companies are developing therapies for End-Stage Renal Disease to improve the treatment scenario. Currently, Aronora Inc. is leading the therapeutics market with its End-Stage Renal Disease drug candidates in the mid to advanced stage of clinical development.
The Leading Companies in the End-Stage Renal Disease Therapeutics Market Include:
Ardelyx
Aronora Inc.
Dynavax Technologies
Ionis Pharmaceuticals
Janssen Research & Development, LLC
Merck
Rockwell Medical Technologies
And Many Others
End-Stage Renal Disease Emerging and Marketed Drugs Covered in the Report Include:
AB002: Aronora, Inc.
HEPLISAV-B: Dynavax Technologies
ISIS 416858: Ionis Pharmaceuticals
MK-2060: Merck
TRIFERIC: Rockwell Medical Technologies
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. End-Stage Renal Disease Competitive Intelligence Analysis
4. End-Stage Renal Disease Market Overview at a Glance
5. End-Stage Renal Disease Disease Background and Overview
6. End-Stage Renal Disease Patient Journey
7. End-Stage Renal Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. End-Stage Renal Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. End-Stage Renal Disease Unmet Needs
10. Key Endpoints of End-Stage Renal Disease Treatment
11. End-Stage Renal Disease Marketed Products
12. End-Stage Renal Disease Emerging Drugs and Latest Therapeutic Advances
13. End-Stage Renal Disease Seven Major Market Analysis
14. Attribute Analysis
15. End-Stage Renal Disease Market Outlook (In US, EU5, and Japan)
16. End-Stage Renal Disease Access and Reimbursement Overview
17. KOL Views on the End-Stage Renal Disease Market
18. End-Stage Renal Disease Market Drivers
19. End-Stage Renal Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
